title: Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?
abstract: Background. Prior studies evaluating the effect of statins or acetylsalicylic acid (ASA) on the survival of men receiving prostate cancer were treatment have reported conflicting results, and have not adjusted for comorbidity. Our aim is to investigate the influence of statins and ASA on prostate cancer survival, when comorbidity is adjusted for, in men treated with external beam radiation therapy (EBRT) for prostate cancer. Methods. A cohort of 3851 patients with prostate cancer treated with curative EBRT ± androgen deprivation therapy (ADT) between 2000 and 2007. Stage, treatment, medication use, and Charlson comorbidity index (CCI) scores were analyzed. Results. Median followup was 8.4 years. Mean age was 70.3 years. Neoadjuvant ADT was used in 67%. Statins were used in 23%, ASA in 24%, and both in 11%. Comorbidity scores were 0 in 65%, 1 in 25%, and ≥2 in 10% of patients. Statin and ASA use were associated with increased age and comorbidity. Although statin and ASA use were significantly associated with improved prostate cancer specific survival (PCSS) on univariate analysis, neither were on multivariate analysis. Conclusion. Neither statin nor ASA use impacted PCSS on multivariate competing risks analysis. Survival was impacted by increased comorbidity as well as statin and ASA use.
authors.affiliation: BC Cancer Agency Radiation Therapy Program, BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6.
authors.forename: J
authors.initials: J
authors.lastname: Caon
authors.affiliation: University of British Columbia, 2329 West Mall, Vancouver, BC, Canada V6T 1Z4.
authors.forename: M
authors.initials: M
authors.lastname: Paquette
authors.affiliation: Cancer Surveillance & Outcomes, Population Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6.
authors.forename: J
authors.initials: J
authors.lastname: Hamm
authors.affiliation: BC Cancer Agency Radiation Therapy Program, BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6 ; University of British Columbia, 2329 West Mall, Vancouver, BC, Canada V6T 1Z4.
authors.forename: T
authors.initials: T
authors.lastname: Pickles
references.citation: IUBMB Life. 2010 Aug;62(8):584-90
references.pmid: 20665620
references.citation: Expert Rev Anticancer Ther. 2010 Oct;10(10):1563-7
references.pmid: 20942627
references.citation: Urology. 2005 Dec;66(6):1150-4
references.pmid: 16360430
references.citation: Cancer. 2010 Jul 15;116(14):3389-98
references.pmid: 20586112
references.citation: J Chronic Dis. 1987;40(5):373-83
references.pmid: 3558716
references.citation: Oncol Rep. 2005 Apr;13(4):559-83
references.pmid: 15756426
references.citation: Cancer Prev Res (Phila). 2012 Oct;5(10):1223-8
references.pmid: 22961777
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2651-2
references.pmid: 20421530
references.citation: Arch Intern Med. 2000 Aug 14-28;160(15):2363-8
references.pmid: 10927735
references.citation: Am J Epidemiol. 2005 Aug 15;162(4):318-25
references.pmid: 16014776
references.citation: Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):713-8
references.pmid: 20452139
references.citation: Actas Urol Esp. 2009 Apr;33(4):351-5
references.pmid: 19579884
references.citation: Prostate. 2011 Feb 15;71(3):298-304
references.pmid: 20717902
references.citation: Cancer. 2010 Apr 1;116(7):1820-6
references.pmid: 20143436
references.citation: Urology. 2009 Jan;73(1):158-62
references.pmid: 18722651
references.citation: Urology. 2011 Jun;77(6):1508.e1-7
references.pmid: 21624609
references.citation: Clin Adv Hematol Oncol. 2003 Nov;1(11):673-8
references.pmid: 16258469
references.citation: J Urol. 2010 Jan;183(1):118-24
references.pmid: 19913252
references.citation: Cancer. 1984 May 15;53(10):2046-52
references.pmid: 6322957
references.citation: J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8
references.pmid: 18957682
references.citation: Eur J Cancer. 2000 Mar;36(4):453-71
references.pmid: 10717521
references.citation: Int J Cancer. 2005 Apr 20;114(4):643-7
references.pmid: 15578694
references.citation: J Urol. 2010 Aug;184(2):494-9
references.pmid: 20620405
references.citation: J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25
references.pmid: 17179483
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2653-9
references.pmid: 20421534
references.citation: Prostate. 2007 Jul 1;67(10):1061-9
references.pmid: 17469127
references.citation: J Natl Cancer Inst. 2007 Apr 18;99(8):608-15
references.pmid: 17440162
references.citation: Eur J Cancer. 2013 Mar;49(4):938-45
references.pmid: 23079475
references.citation: Prostate Cancer Prostatic Dis. 2011 Mar;14(1):63-8
references.pmid: 20938462
references.citation: N Engl J Med. 2000 Jun 29;342(26):1953-8
references.pmid: 10874063
references.citation: J Clin Oncol. 2004 Jun 15;22(12):2388-94
references.pmid: 15197200
references.citation: Lancet Oncol. 2007 May;8(5):395-402
references.pmid: 17466896